文献速递白血病MDS 与骨髓增殖性肿瘤

急性髓系白血病和高危骨髓增生异常综合征的门诊强化诱导化疗

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.
PubMed 文献 · Blood Adv · 2020-01-01

这项先导研究探讨了成人急性髓系白血病(AML)和高危骨髓增生异常综合征(MDS)患者接受门诊强化初始或挽救性诱导化疗的安全性和可行性。筛选标准为无显著器官功能障碍且治疗相关死亡率(TRM)评分对应的第28天死亡率低于5%至10%。精确95%CI,55.8-95.3)在门诊完成诱导化疗,3例因并发症入院,无患者在诱导化疗开始后14天内死亡(精确95%CI,0-22.9)。

要点

  • 选择无显著器官功能障碍且TRM评分对应第28天死亡率<5%-10%的AML/高危MDS患者可考虑门诊诱导化疗。
  • 17例接受治疗的患者中14例(82.4%)在门诊完成诱导化疗,3例因中性粒细胞缺乏伴发热或3级黏膜炎入院。
  • 由护士、社会工作者、医疗提供者和药师组成的团队是门诊诱导化疗成功实施的关键。

核心结论

  • 在经选择的AML和高危MDS患者中,门诊完成强化诱导化疗是可行的。

主要发现

  • 14例患者(82.4%;精确95%CI,55.8-95.3)在门诊完成诱导化疗给药。
  • 3例患者在化疗给药期间入院,2例因中性粒细胞缺乏伴发热,1例因3级黏膜炎。
  • 无患者在诱导化疗开始后14天内死亡(精确95%CI,0-22.9)。

关键数值与推荐

  • 入组条件为无显著器官功能障碍且TRM评分对应的第28天死亡率低于5%至10%。

临床怎么用

  • 对符合筛选标准的AML和高危MDS患者,可在由护士、社会工作者、医疗提供者和药师组成的团队支持下实施门诊强化诱导化疗。

局限性

  • 本研究为先导研究,样本量小(17例接受治疗),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To improve patient quality of life and reduce health care costs, many conditions formerly thought to require inpatient care are now treated in the outpatient setting. Outpatient induction chemotherapy for acute myeloid leukemia (AML) may confer similar benefits. This possibility prompted a pilot study to explore the safety and feasibility of intensive outpatient initial or salvage induction chemotherapy administration for adults with AML and high-risk myelodysplastic syndrome (MDS). Patients with no significant organ dysfunction and a treatment-related mortality (TRM) score corresponding to a day 28 mortality rate of <5% to 10% were eligible for study. Patients were treated as outpatients with daily evaluation by providers and only admitted to the hospital if mandated by complications. Twenty patients were consented, and 17 were treated. Eight patients received initial induction chemotherapy and 9 received salvage induction chemotherapy. Fourteen patients completed induction chemotherapy administration in the outpatient setting (82.4%; exact 95% confidence interval [CI], 55.8-95.3). Three patients were admitted during the course of chemotherapy administration, 2 for neutropenic fever and 1 for grade 3 mucositis. No patients died within 14 days of the initiation of induction chemotherapy (exact 95% CI, 0-22.9). Results of this pilot study suggest it is feasible to complete outpatient induction chemotherapy in select patients with AML and high-risk MDS. A team including nurses, social workers, medical providers, and pharmacists was key to the successful implementation of outpatient induction.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mabrey FL, Gardner KM, Shannon Dorcy K, et al. Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Adv. 2020. PMID: 32074276. doi:10.1182/bloodadvances.2019000707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。